AG
AKBA icon

Algert Global’s Akebia Therapeutics AKBA Stock Holding History

Algert Global’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-21,166
Closed -$15K – 1190
2022
Q1 		$15K Buy
+21,166
New +$45.3K ﹤0.01% 1162
2019
Q1 		– Sell
-19,620
Closed -$108K – 302
2018
Q4 		$108K Buy
+19,620
New +$154K 0.03% 351

Other funds holding AKBA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Algert Global's AKBA Position: Q2 2022 in Review

Algert Global sold out of Akebia Therapeutics (AKBA) in Q2 2022, closing a stake of 21,166 shares — an estimated $15K sold.

Algert Global first reported a position in AKBA in Q4 2018 and held it in 2 quarters. The position peaked at $108K in Q4 2018. 96 funds tracked by Wall St. Rank hold AKBA as of Q2 2022.

  • Algert Global reported no remaining Akebia Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Algert Global sold 21,166 Akebia Therapeutics shares in Q2 2022, an estimated $15K.
  • Algert Global first reported a position in Akebia Therapeutics in Q4 2018 and held it in 2 quarters.
  • Algert Global's Akebia Therapeutics position peaked at $108K in Q4 2018.
  • 96 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2022.

Based on Algert Global's 13F filing for Q2 2022, filed 15 Aug 2022.